Trial reportCytometry. Part B, Clinical cytometry2019
Flow Cytometry Assessment of CD26
Trial report in Cytometry. Part B, Clinical cytometry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04312607 (Value of CD26 Positive Stem Cell Marker in Patients With Classical Myeloproliferative Neoplasms), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Value of CD26 Positive Stem Cell Marker in Patients With Classical Myeloproliferative Neoplasms
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Flow Cytometry Assessment of CD26Cytometry. Part B, Clinical cytometry · 2019Trial
- CD56Mediterranean journal of hematology and infectious diseases · 2026Article
- Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML).Stem cells translational medicine · 2025Article
- Article
- Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission.Clinical and experimental medicine · 2025Article
- Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia.International journal of molecular sciences · 2025Review
- The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers.Frontiers in oncology · 2025Review
- Association of serum and salivary dipeptidyl peptidase-4 (DPP-4) with oral cancerous and precancerous lesions; an observational diagnostic accuracy study.BMC oral health · 2024Observational
- Article
- Article
- Applications of Machine Learning in Chronic Myeloid Leukemia.Diagnostics (Basel, Switzerland) · 2023Review
- The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities.Current hematologic malignancy reports · 2023Review
- Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review.Journal of blood medicine · 2023Review
- Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26Frontiers in pharmacology · 2023Article
- B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.International journal of molecular sciences · 2022Review
- Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.American journal of hematology · 2022Review
- CD26/DPP-4 in Chronic Myeloid Leukemia.Cancers · 2022Review
- Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia.Leukemia research reports · 2022Article
- Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.Cancers · 2021Review
- Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 18 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent investigations in chronic myeloid leukemia (CML) have focused on the identification and characterization of leukemic stem cells (LSCs). These cells reside within the CD34
methodsCD26
resultsThe expression of CD26 on CD34
conclusionsWe propose flow cytometry evaluation of CD26 expression on PB CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.